Awarded $14 Million Multi-Year NIH Grant and Initiated Second Clinical Trial for Breakthrough Therapy PF614-MPARSubmitted Pivotal PF614 Phase 3 Protocol to the FDA for Review SAN DIEGO, CA / ...
Third Quarter Revenue Growth of 12%Reaffirms Full Year 2024 Revenue Guidance of $116 Million to $120 MillionRepresenting Growth of 27% to 31% BELGRADE, MT / ACCESSWIRE / November 12, 2024 / Xtant ...
HAIFA, ISRAEL / ACCESSWIRE / November 12, 2024 / Pluri Inc. (NASDAQ:PLUR), a leading biotechnology company that offers cell-based solutions for various industries. The company will be available for ...
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position ...